Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

NCT03029351 is registered in ClinicalTrials.gov with University at Buffalo as lead sponsor.

NCT NCT03029351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03029351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
Lead sponsor
University at Buffalo
Phase
Phase 4
Overall status
Terminated
Start date
January 10, 2017
Completion date
July 31, 2019
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney diseases, type2 diabetes